sodium (2S,5R,6R)-6-[(2S)-2-(4-ethyl-2,3-dioxopiperazine-1-carbonylamino)-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: sodium (2S,5R,6R)-6-[(2S)-2-(4-ethyl-2,3-dioxopiperazine-1-carbonylamino)-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
• 英文别名: sodium;(2S,5R,6R)-6-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
• 化学式: C23H26N5NaO7S
• 分子量: 539.5
• InChiKey: WCMIIGXFCMNQDS-QMJSIVKPSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -4.57
• 重原子数：
  37
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  185
• 氢给体数：
  2
• 氢受体数：
  8

ADMET

毒理性

• 肝毒性

静脉注射哌拉西林的患者中，多达12%的患者可能会出现短暂且轻至中度的血清转氨酶升高，但这些升高的临床意义不大，并不比其他类似的静脉注射抗生素更常见。与哌拉西林相关的广谱脲酶青霉素类药物美洛西林更常报告有肝损伤，该药物已被停用。在接受哌拉西林的人中，罕见有个体对肝脏损伤的特异反应的报道。肝脏损伤通常是胆汁淤积性的，开始治疗后的1到6周内出现。这种损伤可能很严重，但一旦停止使用哌拉西林，通常是自限性的。肝毒性的特征与其他青霉素类药物相似。哌拉西林和其他青霉素类药物引起的胆汁淤积性肝炎可能持续较长时间，导致持续性胆汁淤积（消失胆管综合征）或血清碱性磷酸酶持续升高，提示部分胆管丢失。与哌拉西林相关的多数肝脏损伤案例都与哌拉西林与β-内酰胺酶抑制剂他唑巴坦（Zosyn及其仿制药）的联合使用有关，这种联合用药比单独使用哌拉西林更常见。

Patients on intravenous piperacillin may have transient and mild-to-moderate serum aminotransferase elevations in up to 12% of patients, but these are of little clinical significance and not more common than with comparative parenteral antibiotics. Hepatic injury was more commonly reported with mezlocillin, a related extended spectrum ureidopenicillin which has been withdrawn from use. Rare instances of idiosyncratic liver injury have been reported in persons receiving piperacillin. The liver injury is typically cholestatic arising within 1 to 6 weeks of starting therapy. The injury can be severe, but is generally self-limited once piperacillin is stopped. The features of the hepatotoxicity resemble those of other penicillins. The cholestatic hepatitis caused by piperacillin and other penicillins can be prolonged and lead to persistent cholestasis (vanishing bile duct syndrome) or persistent elevations in serum alkaline phosphatase suggestive of partial bile duct loss. Most cases of liver injury related to piperacillin are linked to the combination of piperacillin with the beta-lactamase inhibitor tazobactam (Zosyn and generics), which is more commonly used than piperacillin alone.

来源:LiverTox

反应信息

• 作为产物：
  描述：

  piperacillin 生成 sodium (2S,5R,6R)-6-[(2S)-2-(4-ethyl-2,3-dioxopiperazine-1-carbonylamino)-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
  参考文献：
  名称：

  BOOP, D. C.;BERNADY, K. F.

  摘要：

  DOI：

文献信息

• Use of oxygen antagonists for the therapeutic treatment of mammals
  申请人：Fred Hutchinson Cancer Research Center

  公开号：EP2363022A2

  公开（公告）日：2011-09-07

  There is provided the use of oxygen antagonists for inducing stasis in cells, tissues and/or organs in vivo or in an organism overall. It includes methods and apparatuses for achieving stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia and cancer is provided.

  本发明提供了使用氧拮抗剂诱导体内或整个生物体内的细胞、组织和/或器官停滞的方法。它包括在任何这些生物材料中实现停滞的方法和装置，以便保存和/或保护它们。在具体的实施方案中，提供了用于器官移植、热疗、伤口愈合、失血性休克、旁路手术的心脏麻痹、神经变性、低体温和癌症的治疗方法和装置。
• USE OF OXYGEN ANTAGONISTS FOR EX VIVO PRESERVATION OF TISSUES OR ORGANS
  申请人：Fred Hutchinson Cancer Research Center

  公开号：EP2949212A1

  公开（公告）日：2015-12-02

  There is provided the use of oxygen antagonists for inducing stasis in cells, tissues and/or organs in vivo or in an organism overall. It includes methods and apparatuses for achieving stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia and cancer is provided.

  本发明提供了使用氧拮抗剂诱导体内或整个生物体内的细胞、组织和/或器官停滞的方法。它包括在任何这些生物材料中实现停滞的方法和装置，以便保存和/或保护它们。在具体的实施方案中，提供了用于器官移植、热疗、伤口愈合、失血性休克、旁路手术的心脏麻痹、神经变性、低体温和癌症的治疗方法和装置。
• Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
  申请人：Roth B. Mark

  公开号：US20050136125A1

  公开（公告）日：2005-06-23

  The present invention concerns the use of oxygen antagonists for inducing stasis in cells, tissues, and/or organs in vivo or in an organism overall. It includes methods and apparatuses for achieving stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer is provided.

  本发明涉及使用氧拮抗剂诱导体内或整个生物体内的细胞、组织和/或器官停滞。它包括在任何这些生物材料中实现停滞的方法和装置，以便保存和/或保护它们。在具体的实施方案中，提供了用于器官移植、热疗、伤口愈合、失血性休克、旁路手术的心脏麻痹、神经变性、低体温和癌症的治疗方法和装置。
• Methods, compositions and devices for inducing stasis in tissues and organs
  申请人：Roth B. Mark

  公开号：US20050147692A1

  公开（公告）日：2005-07-07

  The present invention concerns the use of oxygen antagonists for inducing stasis in tissue, including all or part of organs. It includes methods and apparatuses for achieving stasis in tissue, so as to preserve and/or protect them. In specific embodiments, preservation methods and apparatuses for preserving tissue for transplantation purposes is provided.

  本发明涉及使用氧拮抗剂诱导组织停滞，包括全部或部分器官。本发明包括实现组织停滞的方法和装置，以便保存和/或保护组织。在具体的实施方案中，本发明提供了为移植目的保存组织的保存方法和装置。
• Methods, compositions and devices for inducing stasis in cells
  申请人：Roth B. Mark

  公开号：US20050170019A1

  公开（公告）日：2005-08-04

  The present invention concerns the use of oxygen antagonists for inducing stasis in cells. It includes methods and apparatuses for achieving stasis in cells, so as to preserve and/or protect them. In specific embodiments, preservation methods and apparatuses for storing platelets is provided.

  本发明涉及使用氧拮抗剂诱导细胞停滞。它包括实现细胞停滞的方法和装置，以便保存和/或保护细胞。在具体的实施方案中，提供了用于储存血小板的保存方法和装置。